Yatiri Bio attended the 65th annual American Society for Hematology meeting in San Diego, CA from December 9 – 12. Yatiri Bio was fortunate to be selected for a poster presentation that highlights the further development of our technology for drug discovery and therapeutic positioning. This platform integrates cutting-edge proteomics with ex vivo drug sensitivity to develop a machine learning model predictive of AML patient outcomes. Our results identify biomarkers that stratify a patient population sensitive to Venetoclax.  Venetoclax is a significant therapy being utilized for the treatment of Acute Myeloid Leukemia (AML) and this research aims to bring the advantages of precision medicine to those patients.

Our poster can be viewed by clicking on the below link:

IDENTIFICATION OF A NOVEL AML PATIENT SUBSET SENSITIVE TO VENETOCLAX USING MATCHED PROTEOMICS AND DIVERSE EX VIVO MODELS